Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690921 · ClinicalTrials.gov registry record · Phase 2
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT03690921: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT03690921 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03690921, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer. LET-IMPT is a type of radiation therapy that uses high energy proton "beamlets" to "paint" the radiation dose into the target and may help to kill tumor cells and shrink tumors. Giving LET-IMPT and standard chemotherapy may work better in treating patients with anal canal squamous cell cancer.
Interventions
- DRUG Cisplatin
- DRUG Fluorouracil
- OTHER Questionnaire Administration
- PROCEDURE Quality-of-Life Assessment
- RADIATION Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2022-06-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690921
The ClinicalTrials.gov registry entry for NCT03690921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT03690921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03690921 about?
NCT03690921 is a clinical study titled "Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial". This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer. LET-IMPT is a type of radiation therapy that uses high energy proton "beamlets" to "paint" the radiation d...
What is the current status of trial NCT03690921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2018-11-08. Estimated completion is 2022-06-03.
What interventions are being tested in trial NCT03690921?
The interventions under investigation include: Cisplatin (DRUG), Fluorouracil (DRUG), Questionnaire Administration (OTHER), Quality-of-Life Assessment (PROCEDURE), Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy (RADIATION).
Who is sponsoring clinical trial NCT03690921?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.